In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme

Showing 151 to 200 of 217

TitleTypeExpected publication date
Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]Technology appraisal guidanceTBC
Pembrolizumab with chemotherapy with or without bevacizumab for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments ID6363Technology appraisal guidanceTBC
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]Technology appraisal guidanceTBC
Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]Technology appraisal guidanceTBC
Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]Technology appraisal guidanceTBC
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]Technology appraisal guidanceTBC
Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]Technology appraisal guidance
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]Technology appraisal guidanceTBC
Plozasiran for treating familial chylomicronaemia syndrome [ID6593]Technology appraisal guidance
Polihexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]Technology appraisal guidance
Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases [ID6512]Technology appraisal guidance
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]Technology appraisal guidance
Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines ID6356Technology appraisal guidance
Repotrectinib for treating NTRK fusion-positive advanced solid tumours in people 12 years and over [TSID12147]Technology appraisal guidanceTBC
Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]Technology appraisal guidanceTBC
Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]Technology appraisal guidance
Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy ID6482 [ID6482]Technology appraisal guidanceTBC
Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]Technology appraisal guidanceTBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]Technology appraisal guidanceTBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]Technology appraisal guidanceTBC
Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565]Technology appraisal guidanceTBC
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]Technology appraisal guidanceTBC
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]Technology appraisal guidanceTBC
Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]Technology appraisal guidanceTBC
Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]Technology appraisal guidanceTBC
Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer untreated with BCG ID6454Technology appraisal guidanceTBC
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284]Technology appraisal guidanceTBC
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]Technology appraisal guidanceTBC
Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]Technology appraisal guidanceTBC
Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 [ID6385]Technology appraisal guidanceTBC
Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458]Technology appraisal guidance
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over ID6542Technology appraisal guidance
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (review of HST31) [ID6598]Highly specialised technology
Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]Technology appraisal guidanceTBC
Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439]Technology appraisal guidance
Sonrotoclax for treating relapsed or refractory mantle cell lymphoma after an anti-CD20 treatment and a BTK inhibitor [ID6654]Technology appraisal guidanceTBC
Sotatercept for treating pulmonary arterial hypertension [ID6163]Technology appraisal guidanceTBC
Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over TSID 12091Technology appraisal guidanceTBC
Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632Technology appraisal guidanceTBC
Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments ID6413Technology appraisal guidance
Targeted-release budesonide for treating primary IgA nephropathy (review of TA937) [ID6485]Technology appraisal guidance
Tarlatamamb for treating extensive stage small-cell lung cancer that has progressed after platinum-based chemotherapy [ID6617]Technology appraisal guidanceTBC
Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]Technology appraisal guidance
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]Technology appraisal guidanceTBC
Teprotumumab for treating thyroid eye disease [ID6432]Technology appraisal guidanceTBC
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps ID6379Technology appraisal guidance
Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]Technology appraisal guidanceTBC
Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250]Technology appraisal guidanceTBC
Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment [ID3753]Technology appraisal guidance
Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]Highly specialised technologyTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All